Somewhat Positive Media Coverage Somewhat Unlikely to Impact Zoetis (ZTS) Share Price
News stories about Zoetis (NYSE:ZTS) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zoetis earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.6363792215495 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s scoring:
- Watch for Zoetis Inc to Potentially Pullback After Gaining 1.50% Yesterday (mysmartrend.com)
- Zoetis Inc. (ZTS) registers a price change of -0.02% while Zynerba Pharmaceuticals, Inc. (ZYNE) finishes with a flow … – Stocks Gallery (stocksgallery.com)
- Zoetis (ZTS): Clavamox Chewable antibiotic Study Success Underscores Positive Thesis – Cantor – StreetInsider.com (streetinsider.com)
- Zoetis Inc. (NYSE:ZTS) PT Set at $75.00 by Cantor Fitzgerald (americanbankingnews.com)
- Zoetis Inc. (NYSE:ZTS) Position Cut by Argus Investors Counsel Inc (campdesrecrues.com)
Shares of Zoetis (NYSE ZTS) traded up 0.48% during mid-day trading on Tuesday, reaching $61.03. The company had a trading volume of 2,220,781 shares. The company has a market capitalization of $29.85 billion, a PE ratio of 34.50 and a beta of 1.02. The stock’s 50-day moving average price is $62.14 and its 200 day moving average price is $58.11. Zoetis has a 1-year low of $46.86 and a 1-year high of $63.85.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.49 EPS. Equities analysts expect that Zoetis will post $2.34 EPS for the current year.
ZTS has been the subject of a number of research reports. Jefferies Group LLC increased their target price on Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, May 9th. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the company a “buy” rating in a research report on Monday. Argus reiterated a “buy” rating and set a $69.00 target price (up from $60.00) on shares of Zoetis in a research report on Tuesday, May 30th. CL King initiated coverage on Zoetis in a research report on Friday, May 26th. They set a “buy” rating and a $71.00 target price for the company. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $65.00 target price (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $64.78.
TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-zoetis-zts-share-price.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.